Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Showing products 1–24 of 25. More products

AMOXICILLIN & CLAVULANIC ACID

Form:

24 of 24 products shown

22 general benefit · 2 not a benefit

Other products in the same Health Canada class (J01C, J01CR) — coverage varies; not interchangeable

  • Piperacillin + tazobactam (Tazocin): not a benefit
  • Amoxicillin (Novamoxin): general benefit, Not a benefit, Listing status unconfirmed
  • Ampicillin (Penbritin): general benefit, Not a benefit
  • Cloxacillin (Orbenin): general benefit, Not a benefit
  • Penicillin v (Nadopen-V): general benefit, Not a benefit

Clavulin · DIN 01916882 · 25mg & 6.25mg/mL · oral liquid

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Clavulin · DIN 01916882 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-10-01 Daily cost (source): $1.8975 Health Canada: Marketed since 2003-02-10 · brand CLAVULIN 125 F ORAL SUS · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients CLAVULANIC ACID (CLAVULANATE POTASSIUM) 31.25 MG/5ML, AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 125 MG/5ML · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Clavulin: Formulary list price $0.1265/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1265 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15208 · Verify on the e-Formulary ↗ (DIN 01916882)

Source record
DIN 01916882: Clavulin Raw flags: sec3=Y Item: 081216054; group id 26; item number 0048; lccId None; manufacturer id GSK Source form: O/L; strength: 25mg & 6.25mg/mL Recorded listing: General benefit Source prices (unrounded): $0.1265; ministry $0.1265 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01916882 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15208
Shortage status: resolved shortage (ended 2023-06-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01916882
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Clavulin · DIN 01916874 · 50mg & 12.5mg/mL · oral liquid

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Clavulin · DIN 01916874 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-10-01 Daily cost (source): $4.1295 Health Canada: Marketed since 2003-01-31 · brand CLAVULIN 250 F ORAL SUS · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients CLAVULANIC ACID (CLAVULANATE POTASSIUM) 62.5 MG/5ML, AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 250 MG/5ML · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1216 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15209 · Verify on the e-Formulary ↗ (DIN 01916874)

Source record
DIN 01916874: Clavulin Raw flags: sec3=Y Item: 081216053; group id 26; item number 0049; lccId None; manufacturer id GSK Source form: O/L; strength: 50mg & 12.5mg/mL Recorded listing: General benefit Source prices (unrounded): $0.2753; ministry $0.1216 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01916874 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15209
Interchangeable products
Jamp Amoxi Clav Suspension · DIN 02539438 · $0.1216 M-Amoxi Clav · DIN 02542226 · $0.1216
Shortage status: resolved shortage (ended 2023-03-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01916874
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Amoxi Clav Suspension · DIN 02539438 · 50mg & 12.5mg/mL · oral liquid

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Amoxi Clav Suspension · DIN 02539438 Manufacturer: Jamp Pharma Corporation; listing date 2024-09-27 Daily cost (source): $1.8240 Health Canada: Marketed since 2024-07-22 · brand JAMP AMOXI CLAV SUSPENSION · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients CLAVULANIC ACID (CLAVULANATE POTASSIUM) 62.5 MG/5ML, AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 250 MG/5ML · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Amoxi Clav Suspension: Formulary list price $0.1216/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1216 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102818 · Verify on the e-Formulary ↗ (DIN 02539438)

Source record
DIN 02539438: Jamp Amoxi Clav Suspension Raw flags: sec3=Y Item: 081216053; group id 26; item number 0049; lccId None; manufacturer id JPC Source form: O/L; strength: 50mg & 12.5mg/mL Recorded listing: General benefit Source prices (unrounded): $0.1216; ministry $0.1216 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02539438 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102818
Interchangeable products
Clavulin · DIN 01916874 · $0.1216 M-Amoxi Clav · DIN 02542226 · $0.1216
Shortage status: active shortage (reported 2026-03-12, estimated to end 2026-07-31, last updated 2026-07-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02539438
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Amoxi Clav · DIN 02542226 · 50mg & 12.5mg/mL · oral liquid

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Amoxi Clav · DIN 02542226 Manufacturer: Mantra Pharma Inc.; listing date 2024-03-28 Daily cost (source): $1.8240 Health Canada: Marketed since 2024-02-01 · brand M-AMOXI CLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients CLAVULANIC ACID (CLAVULANATE POTASSIUM) 62.5 MG/5ML, AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 250 MG/5ML · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

M-Amoxi Clav: Formulary list price $0.1216/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1216 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103081 · Verify on the e-Formulary ↗ (DIN 02542226)

Source record
DIN 02542226: M-Amoxi Clav Raw flags: sec3=Y Item: 081216053; group id 26; item number 0049; lccId None; manufacturer id MAT Source form: O/L; strength: 50mg & 12.5mg/mL Recorded listing: General benefit Source prices (unrounded): $0.1216; ministry $0.1216 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02542226 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103081
Interchangeable products
Clavulin · DIN 01916874 · $0.1216 Jamp Amoxi Clav Suspension · DIN 02539438 · $0.1216
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02542226
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Clavulin (BID) · DIN 02238831 · 200mg & 28.5mg/5mL · suspension

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Clavulin (BID) · DIN 02238831 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2000-01-17 Health Canada: Marketed since 2003-01-15 · brand CLAVULIN 200 · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 200 MG/5ML, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 28.5 MG/5ML · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1007 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62269 · Verify on the e-Formulary ↗ (DIN 02238831)

Source record
DIN 02238831: Clavulin (BID) Raw flags: sec3=Y Item: 081216081; group id 26; item number 0050; lccId None; manufacturer id GSK Source form: Susp; strength: 200mg & 28.5mg/5mL Recorded listing: General benefit Source prices (unrounded): $0.1974; ministry $0.1007 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02238831 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62269
Interchangeable products
Jamp Amoxi Clav Suspension · DIN 02539411 · $0.1007
Shortage status: resolved shortage (ended 2023-06-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02238831
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Amoxi Clav · DIN 02243350 · 250mg & 125mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Amoxi Clav · DIN 02243350 Manufacturer: Apotex Inc.; listing date 2001-10-11 Daily cost (source): $0.7401 Health Canada: Marketed since 2020-02-10 · brand APO-AMOXI CLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG, AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 250 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Amoxi Clav: Formulary list price $0.2467/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2467 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67257 · Verify on the e-Formulary ↗ (DIN 02243350)

Source record
DIN 02243350: Apo-Amoxi Clav Raw flags: sec3=Y Item: 081216052; group id 26; item number 0052; lccId None; manufacturer id APX Source form: Tab; strength: 250mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.2467; ministry $0.2467 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243350 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67257
Interchangeable products
Auro-Amoxiclav · DIN 02471671 · $0.2467 Clavulin · DIN 01916866 · not recorded Jamp Amoxi Clav · DIN 02508249 · $0.2467
Shortage status: shortage reported ended 2026-04-23 (report last updated 2026-04-23); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243350
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Amoxiclav · DIN 02471671 · 250mg & 125mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Amoxiclav · DIN 02471671 Manufacturer: Auro Pharma Inc.; listing date 2022-04-29 Daily cost (source): $0.7401 Health Canada: Marketed since 2022-03-03 · brand AURO-AMOXICLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG, AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 250 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Amoxiclav: Formulary list price $0.2467/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2467 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96090 · Verify on the e-Formulary ↗ (DIN 02471671)

Source record
DIN 02471671: Auro-Amoxiclav Raw flags: sec3=Y Item: 081216052; group id 26; item number 0052; lccId None; manufacturer id AUR Source form: Tab; strength: 250mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.2467; ministry $0.2467 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02471671 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96090
Interchangeable products
Apo-Amoxi Clav · DIN 02243350 · $0.2467 Clavulin · DIN 01916866 · not recorded Jamp Amoxi Clav · DIN 02508249 · $0.2467
Shortage status: resolved shortage (ended 2025-02-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02471671
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Amoxi Clav · DIN 02508249 · 250mg & 125mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Amoxi Clav · DIN 02508249 Manufacturer: Jamp Pharma Corporation; listing date 2022-02-28 Daily cost (source): $0.7401 Health Canada: Marketed since 2021-12-24 · brand JAMP AMOXI CLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG, AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 250 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Amoxi Clav: Formulary list price $0.2467/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2467 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99763 · Verify on the e-Formulary ↗ (DIN 02508249)

Source record
DIN 02508249: Jamp Amoxi Clav Raw flags: sec3=Y Item: 081216052; group id 26; item number 0052; lccId None; manufacturer id JPC Source form: Tab; strength: 250mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.2467; ministry $0.2467 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02508249 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99763
Interchangeable products
Apo-Amoxi Clav · DIN 02243350 · $0.2467 Auro-Amoxiclav · DIN 02471671 · $0.2467 Clavulin · DIN 01916866 · not recorded
Shortage status: resolved shortage (ended 2026-04-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02508249
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Clavulin (BID) · DIN 02238830 · 400mg & 57mg/5mL · suspension

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Clavulin (BID) · DIN 02238830 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2000-01-17 Health Canada: Marketed since 2002-12-17 · brand CLAVULIN 400 · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients CLAVULANIC ACID (CLAVULANATE POTASSIUM) 57 MG/5ML, AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 400 MG/5ML · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1591 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62268 · Verify on the e-Formulary ↗ (DIN 02238830)

Source record
DIN 02238830: Clavulin (BID) Raw flags: sec3=Y Item: 081216082; group id 26; item number 0051; lccId None; manufacturer id GSK Source form: Susp; strength: 400mg & 57mg/5mL Recorded listing: General benefit Source prices (unrounded): $0.3850; ministry $0.1591 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02238830 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62268
Interchangeable products
Jamp Amoxi Clav Suspension · DIN 02539446 · $0.1591 M-Amoxi Clav · DIN 02530694 · $0.1591
Shortage status: resolved shortage (ended 2023-03-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02238830
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Amoxi Clav Suspension · DIN 02539446 · 400mg & 57mg/5mL · suspension

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Amoxi Clav Suspension · DIN 02539446 Manufacturer: Jamp Pharma Corporation; listing date 2024-09-27 Health Canada: Marketed since 2024-07-22 · brand JAMP AMOXI CLAV SUSPENSION · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 400 MG/5ML, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 57 MG/5ML · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Amoxi Clav Suspension: Formulary list price $0.1591/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1591 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102819 · Verify on the e-Formulary ↗ (DIN 02539446)

Source record
DIN 02539446: Jamp Amoxi Clav Suspension Raw flags: sec3=Y Item: 081216082; group id 26; item number 0051; lccId None; manufacturer id JPC Source form: Susp; strength: 400mg & 57mg/5mL Recorded listing: General benefit Source prices (unrounded): $0.1591; ministry $0.1591 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02539446 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102819
Interchangeable products
Clavulin (BID) · DIN 02238830 · $0.1591 M-Amoxi Clav · DIN 02530694 · $0.1591
Shortage status: active shortage (reported 2026-06-30, estimated to end 2026-09-25, last updated 2026-07-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02539446
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Amoxi Clav · DIN 02530694 · 400mg & 57mg/5mL · suspension

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Amoxi Clav · DIN 02530694 Manufacturer: Mantra Pharma Inc.; listing date 2022-12-21 Health Canada: Marketed since 2022-11-24 · brand M-AMOXI CLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 400 MG/5ML, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 57 MG/5ML · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

M-Amoxi Clav: Formulary list price $0.1591/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1591 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101985 · Verify on the e-Formulary ↗ (DIN 02530694)

Source record
DIN 02530694: M-Amoxi Clav Raw flags: sec3=Y Item: 081216082; group id 26; item number 0051; lccId None; manufacturer id MAT Source form: Susp; strength: 400mg & 57mg/5mL Recorded listing: General benefit Source prices (unrounded): $0.1591; ministry $0.1591 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02530694 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101985
Interchangeable products
Clavulin (BID) · DIN 02238830 · $0.1591 Jamp Amoxi Clav Suspension · DIN 02539446 · $0.1591
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02530694
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Amoxicillin/Clav · DIN 02536021 · 500mg & 125mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Amoxicillin/Clav · DIN 02536021 Manufacturer: Sanis Health Inc.; listing date 2024-04-30 Daily cost (source): $1.1334 Health Canada: Marketed since 2024-02-20 · brand AMOXICILLIN/CLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 500 MG, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Amoxicillin/Clav: Formulary list price $0.3778/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3778 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102484 · Verify on the e-Formulary ↗ (DIN 02536021)

Source record
DIN 02536021: Amoxicillin/Clav Raw flags: sec3=Y Item: 081216051; group id 26; item number 0053; lccId None; manufacturer id SAI Source form: Tab; strength: 500mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.3778; ministry $0.3778 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02536021 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102484
Interchangeable products
Apo-Amoxi Clav · DIN 02243351 · $0.3778 Auro-Amoxiclav · DIN 02471698 · $0.3778 Clavulin · DIN 01916858 · not recorded Jamp Amoxi Clav · DIN 02508257 · $0.3778 Sandoz Amoxi-Clav Tablets · DIN 02482576 · $0.3778
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02536021
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Amoxi Clav · DIN 02243351 · 500mg & 125mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Amoxi Clav · DIN 02243351 Manufacturer: Apotex Inc.; listing date 2001-10-11 Daily cost (source): $1.1334 Health Canada: Marketed since 2020-02-10 · brand APO-AMOXI CLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 500 MG, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Amoxi Clav: Formulary list price $0.3778/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3778 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67258 · Verify on the e-Formulary ↗ (DIN 02243351)

Source record
DIN 02243351: Apo-Amoxi Clav Raw flags: sec3=Y Item: 081216051; group id 26; item number 0053; lccId None; manufacturer id APX Source form: Tab; strength: 500mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.3778; ministry $0.3778 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243351 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67258
Interchangeable products
Amoxicillin/Clav · DIN 02536021 · $0.3778 Auro-Amoxiclav · DIN 02471698 · $0.3778 Clavulin · DIN 01916858 · not recorded Jamp Amoxi Clav · DIN 02508257 · $0.3778 Sandoz Amoxi-Clav Tablets · DIN 02482576 · $0.3778
Shortage status: resolved shortage (ended 2025-06-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243351
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Amoxiclav · DIN 02471698 · 500mg & 125mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Amoxiclav · DIN 02471698 Manufacturer: Auro Pharma Inc.; listing date 2022-04-29 Daily cost (source): $1.1334 Health Canada: Marketed since 2022-03-03 · brand AURO-AMOXICLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG, AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 500 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Amoxiclav: Formulary list price $0.3778/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3778 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96091 · Verify on the e-Formulary ↗ (DIN 02471698)

Source record
DIN 02471698: Auro-Amoxiclav Raw flags: sec3=Y Item: 081216051; group id 26; item number 0053; lccId None; manufacturer id AUR Source form: Tab; strength: 500mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.3778; ministry $0.3778 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02471698 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96091
Interchangeable products
Amoxicillin/Clav · DIN 02536021 · $0.3778 Apo-Amoxi Clav · DIN 02243351 · $0.3778 Clavulin · DIN 01916858 · not recorded Jamp Amoxi Clav · DIN 02508257 · $0.3778 Sandoz Amoxi-Clav Tablets · DIN 02482576 · $0.3778
Shortage status: resolved shortage (ended 2025-02-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02471698
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Amoxi Clav · DIN 02508257 · 500mg & 125mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Amoxi Clav · DIN 02508257 Manufacturer: Jamp Pharma Corporation; listing date 2022-02-28 Daily cost (source): $1.1334 Health Canada: Marketed since 2021-12-24 · brand JAMP AMOXI CLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 500 MG, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Amoxi Clav: Formulary list price $0.3778/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3778 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99764 · Verify on the e-Formulary ↗ (DIN 02508257)

Source record
DIN 02508257: Jamp Amoxi Clav Raw flags: sec3=Y Item: 081216051; group id 26; item number 0053; lccId None; manufacturer id JPC Source form: Tab; strength: 500mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.3778; ministry $0.3778 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02508257 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99764
Interchangeable products
Amoxicillin/Clav · DIN 02536021 · $0.3778 Apo-Amoxi Clav · DIN 02243351 · $0.3778 Auro-Amoxiclav · DIN 02471698 · $0.3778 Clavulin · DIN 01916858 · not recorded Sandoz Amoxi-Clav Tablets · DIN 02482576 · $0.3778
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02508257
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Amoxi-Clav Tablets · DIN 02482576 · 500mg & 125mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Amoxi-Clav Tablets · DIN 02482576 Manufacturer: Sandoz Canada Inc.; listing date 2019-04-30 Daily cost (source): $1.1334 Health Canada: Marketed since 2019-03-01 · brand SANDOZ AMOXI-CLAV TABLET · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 500 MG, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Amoxi-Clav Tablets: Formulary list price $0.3778/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3778 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97300 · Verify on the e-Formulary ↗ (DIN 02482576)

Source record
DIN 02482576: Sandoz Amoxi-Clav Tablets Raw flags: sec3=Y Item: 081216051; group id 26; item number 0053; lccId None; manufacturer id SDZ Source form: Tab; strength: 500mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.3778; ministry $0.3778 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02482576 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97300
Interchangeable products
Amoxicillin/Clav · DIN 02536021 · $0.3778 Apo-Amoxi Clav · DIN 02243351 · $0.3778 Auro-Amoxiclav · DIN 02471698 · $0.3778 Clavulin · DIN 01916858 · not recorded Jamp Amoxi Clav · DIN 02508257 · $0.3778
Shortage status: resolved shortage (ended 2025-01-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02482576
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Amoxicillin/Clav · DIN 02536048 · 875mg & 125mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Amoxicillin/Clav · DIN 02536048 Manufacturer: Sanis Health Inc.; listing date 2024-04-30 Health Canada: Marketed since 2024-02-20 · brand AMOXICILLIN/CLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG, AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 875 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Amoxicillin/Clav: Formulary list price $0.5551/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5551 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102485 · Verify on the e-Formulary ↗ (DIN 02536048)

Source record
DIN 02536048: Amoxicillin/Clav Raw flags: sec3=Y Item: 081216080; group id 26; item number 0054; lccId None; manufacturer id SAI Source form: Tab; strength: 875mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.5551; ministry $0.5551 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02536048 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102485
Interchangeable products
Apo-Amoxi Clav · DIN 02245623 · $0.5551 Auro-Amoxiclav · DIN 02471701 · $0.5551 Clavulin (BID) · DIN 02238829 · not recorded Jamp Amoxi Clav · DIN 02508265 · $0.5551 Sandoz Amoxi-Clav Tablets · DIN 02482584 · $0.5551
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02536048
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Amoxi Clav · DIN 02245623 · 875mg & 125mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Amoxi Clav · DIN 02245623 Manufacturer: Apotex Inc.; listing date 2003-09-04 Health Canada: Marketed since 2019-07-03 · brand APO-AMOXI CLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 875 MG, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Amoxi Clav: Formulary list price $0.5551/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5551 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69723 · Verify on the e-Formulary ↗ (DIN 02245623)

Source record
DIN 02245623: Apo-Amoxi Clav Raw flags: sec3=Y Item: 081216080; group id 26; item number 0054; lccId None; manufacturer id APX Source form: Tab; strength: 875mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.5551; ministry $0.5551 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245623 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69723
Interchangeable products
Amoxicillin/Clav · DIN 02536048 · $0.5551 Auro-Amoxiclav · DIN 02471701 · $0.5551 Clavulin (BID) · DIN 02238829 · not recorded Jamp Amoxi Clav · DIN 02508265 · $0.5551 Sandoz Amoxi-Clav Tablets · DIN 02482584 · $0.5551
Shortage status: resolved shortage (ended 2024-04-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245623
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Amoxiclav · DIN 02471701 · 875mg & 125mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Amoxiclav · DIN 02471701 Manufacturer: Auro Pharma Inc.; listing date 2022-04-29 Health Canada: Marketed since 2022-03-03 · brand AURO-AMOXICLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 875 MG, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Amoxiclav: Formulary list price $0.5551/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5551 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96092 · Verify on the e-Formulary ↗ (DIN 02471701)

Source record
DIN 02471701: Auro-Amoxiclav Raw flags: sec3=Y Item: 081216080; group id 26; item number 0054; lccId None; manufacturer id AUR Source form: Tab; strength: 875mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.5551; ministry $0.5551 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02471701 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96092
Interchangeable products
Amoxicillin/Clav · DIN 02536048 · $0.5551 Apo-Amoxi Clav · DIN 02245623 · $0.5551 Clavulin (BID) · DIN 02238829 · not recorded Jamp Amoxi Clav · DIN 02508265 · $0.5551 Sandoz Amoxi-Clav Tablets · DIN 02482584 · $0.5551
Shortage status: resolved shortage (ended 2024-12-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02471701
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Amoxi Clav · DIN 02508265 · 875mg & 125mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Amoxi Clav · DIN 02508265 Manufacturer: Jamp Pharma Corporation; listing date 2022-02-28 Health Canada: Marketed since 2021-12-24 · brand JAMP AMOXI CLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG, AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 875 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Amoxi Clav: Formulary list price $0.5551/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5551 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99765 · Verify on the e-Formulary ↗ (DIN 02508265)

Source record
DIN 02508265: Jamp Amoxi Clav Raw flags: sec3=Y Item: 081216080; group id 26; item number 0054; lccId None; manufacturer id JPC Source form: Tab; strength: 875mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.5551; ministry $0.5551 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02508265 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99765
Interchangeable products
Amoxicillin/Clav · DIN 02536048 · $0.5551 Apo-Amoxi Clav · DIN 02245623 · $0.5551 Auro-Amoxiclav · DIN 02471701 · $0.5551 Clavulin (BID) · DIN 02238829 · not recorded Sandoz Amoxi-Clav Tablets · DIN 02482584 · $0.5551
Shortage status: resolved shortage (ended 2024-05-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02508265
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Amoxi-Clav Tablets · DIN 02482584 · 875mg & 125mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Amoxi-Clav Tablets · DIN 02482584 Manufacturer: Sandoz Canada Inc.; listing date 2019-04-30 Health Canada: Marketed since 2019-03-01 · brand SANDOZ AMOXI-CLAV TABLET · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG, AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 875 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Amoxi-Clav Tablets: Formulary list price $0.5551/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5551 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97301 · Verify on the e-Formulary ↗ (DIN 02482584)

Source record
DIN 02482584: Sandoz Amoxi-Clav Tablets Raw flags: sec3=Y Item: 081216080; group id 26; item number 0054; lccId None; manufacturer id SDZ Source form: Tab; strength: 875mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.5551; ministry $0.5551 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02482584 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97301
Interchangeable products
Amoxicillin/Clav · DIN 02536048 · $0.5551 Apo-Amoxi Clav · DIN 02245623 · $0.5551 Auro-Amoxiclav · DIN 02471701 · $0.5551 Clavulin (BID) · DIN 02238829 · not recorded Jamp Amoxi Clav · DIN 02508265 · $0.5551
Shortage status: resolved shortage (ended 2025-11-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02482584
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Amoxi Clav Suspension · DIN 02539411 · 200mg & 28.5mg/5mL · suspension

General benefitDormant since 2026-08-03 · checked 2026-09-02 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Amoxi Clav Suspension · DIN 02539411 Manufacturer: Jamp Pharma Corporation; listing date 2024-09-27 Health Canada: Dormant since 2026-08-03 · brand JAMP AMOXI CLAV SUSPENSION · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 200 MG/5ML, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 28.5 MG/5ML · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Amoxi Clav Suspension: Formulary list price $0.1007/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1007 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102817 · Verify on the e-Formulary ↗ (DIN 02539411)

Source record
DIN 02539411: Jamp Amoxi Clav Suspension Raw flags: sec3=Y Item: 081216081; group id 26; item number 0050; lccId None; manufacturer id JPC Source form: Susp; strength: 200mg & 28.5mg/5mL Recorded listing: General benefit Source prices (unrounded): $0.1007; ministry $0.1007 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02539411 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102817
Interchangeable products
Clavulin (BID) · DIN 02238831 · $0.1007
Shortage status: active shortage (reported 2024-12-23, estimated to end 2026-12-23, last updated 2026-07-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02539411
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-08-03 — choose a marketed DIN from the same-category list.

Clavulin · DIN 01916866 · 250mg & 125mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-08-02 — choose a marketed DIN from the same-category list.Discontinued 2007-08-02 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-08-02 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2007-08-02 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Clavulin · DIN 01916866 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-10-01 Daily cost (source): $0.7401 Health Canada: Cancelled post market since 2007-08-02 · brand CLAVULIN 250 TAB · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG, AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 250 MG · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Clavulin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18891 · Verify on the e-Formulary ↗ (DIN 01916866)

Source record
DIN 01916866: Clavulin Raw flags: notABenefit=Y, sec3=Y Item: 081216052; group id 26; item number 0052; lccId None; manufacturer id GSK Source form: Tab; strength: 250mg & 125mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01916866 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18891
Interchangeable products
Apo-Amoxi Clav · DIN 02243350 · $0.2467 Auro-Amoxiclav · DIN 02471671 · $0.2467 Jamp Amoxi Clav · DIN 02508249 · $0.2467
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01916866
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2007-08-02 — choose a marketed DIN from the same-category list.

Clavulin · DIN 01916858 · 500mg & 125mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-01-13 — choose a marketed DIN from the same-category list.Discontinued 2024-01-13 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-01-13 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2024-01-13 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Clavulin · DIN 01916858 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-10-01 Daily cost (source): $1.1334 Health Canada: Cancelled post market since 2024-01-13 · brand CLAVULIN 500 F TAB · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 500 MG, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Clavulin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15903 · Verify on the e-Formulary ↗ (DIN 01916858)

Source record
DIN 01916858: Clavulin Raw flags: notABenefit=Y, sec3=Y Item: 081216051; group id 26; item number 0053; lccId None; manufacturer id GSK Source form: Tab; strength: 500mg & 125mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01916858 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15903
Interchangeable products
Amoxicillin/Clav · DIN 02536021 · $0.3778 Apo-Amoxi Clav · DIN 02243351 · $0.3778 Auro-Amoxiclav · DIN 02471698 · $0.3778 Jamp Amoxi Clav · DIN 02508257 · $0.3778 Sandoz Amoxi-Clav Tablets · DIN 02482576 · $0.3778
Shortage status: discontinued (2024-01-31, reported by GLAXOSMITHKLINE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01916858
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2024-01-13 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:12:16 Penicillins) and how they are covered

Matched class: 08:12:16 Penicillins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): AMOXICILLIN, AMPICILLIN, CLOXACILLIN, PENICILLIN V (POTASSIUM) 08:12:16 Penicillins

PIPERACILLIN SODIUM & TAZOBACTAM SODIUM

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2g & 250mg, 3g & 375mg, 4g & 500mg · Inj Pd-2.25g Vial Pk, Inj Pd-3.375g Vial Pk, Inj Pd-4.5g Vial Pk

AMOXICILLIN

· 36 products · General benefit (27), Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (4), Temporary benefit (1) · strengths: 250mg, 500mg, 125mg, 25mg/mL, 50mg/mL · Cap, Chew Tab, O/L, Pd for Oral Susp

AMPICILLIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 250mg, 500mg · Cap

CLOXACILLIN

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 250mg, 500mg, 25mg/mL · Cap, O/L

PENICILLIN V (POTASSIUM)

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 25mg/mL, 300mg · O/L, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:16
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: lower respiratory tract infections
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CEFOXITIN SODIUM · Off-Formulary Interchangeable, not an ODB benefit 5 - Lower respiratory tract infections PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10 Product monograph CEFTRIAXONE DISODIUM · Listed, not a benefit (3), General benefit (10), Off-Formulary Interchangeable, not an ODB benefit (3) • Lower Respiratory tract infections caused by E. coli, H. influenzae, K. pneumoniae and species, Staph. aureus, Strep. pneumoniae and species (excluding enterococci). PM: https://pdf.hres.ca/dpd_pm/00071552.PDF; date MAY 15, 2023; DIN 02289695; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications CLAVULIN (amoxicillin / clavulanate potassium) is indicated for the treatment of the following infections when caused by CLAVULIN-susceptible strains of the designated bacteria: • Sinusitis when caused by β-lactamase producing strains of H. influenzae or Moraxella (Branhamella) catarrhalis. • Otitis Media when caused by β-lactamase producing strains of H. influenzae or Moraxella (Branhamella) catarrhalis. • Lower Respiratory Tract Infections when caused by β-lactamase producing strains of H. influenzae, K. pneumoniae, S. aureus or Moraxella (Branhamella) catarrhalis. • Skin and Soft Tissue Infections when caused by β-lactamase producing strains of S. aureus. • Urinary Tract Infections when caused by β-lactamase producing strains of E. coli. While CLAVULIN is indicated only for the conditions listed above, infections caused by ampicillin (amoxicillin) susceptible organisms are also amenable to CLAVULIN treatment due to its amoxicillin content. Furthermore, mixed infections caused by organisms susceptible to ampicillin (amoxicillin) and β-lactamase producing organisms susceptible to CLAVULIN should not require the addition of another an… https://pdf.hres.ca/dpd_pm/00084428.PDF PM date: 2026-04-24 Source product: CLAVULIN 250 F ORAL SUS; DIN 01916874; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Jamp Amoxi Clav Suspension · DIN 02539438 Shortage status: active shortage (reported 2026-03-12, estimated to end 2026-07-31, last updated 2026-07-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02539438

Check this DIN again

Apo-Amoxi Clav · DIN 02243350 Shortage status: shortage reported ended 2026-04-23 (report last updated 2026-04-23); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243350

Check this DIN again

Jamp Amoxi Clav Suspension · DIN 02539446 Shortage status: active shortage (reported 2026-06-30, estimated to end 2026-09-25, last updated 2026-07-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02539446

Check this DIN again

Jamp Amoxi Clav Suspension · DIN 02539411 Shortage status: active shortage (reported 2024-12-23, estimated to end 2026-12-23, last updated 2026-07-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02539411

Check this DIN again

Clavulin · DIN 01916858 Shortage status: discontinued (2024-01-31, reported by GLAXOSMITHKLINE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01916858

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Clavulin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026